Technology Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion By Reuters - April 28, 2026 0 115 FacebookTwitterPinterestWhatsApp AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. Read more…